The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.

The entities involved

• FDA →
  • Lawsuits filed in Seattle involve FDA oversight, while the FDA investigates food safety issues in New Jersey.10:53
  • FDA approval supports NDA submission in Aurora.05:59
• Hoffmann-La Roche →

  Swiss healthcare company

  • Brazilian regulator banned Amazon listings and found Roche products being sold illegally on the platform.10:07
  • FactSet reported the latest sales figures for Hoffmann-La Roche.Thu 15:17
• Biogen →

  American multinational biotechnology company

  • Financial firms, including Jefferies, RBC, and Wells Fargo, issued rating and price objective updates for Biogen.08:51
  • Apellis is acquired by Biogen, and Aspaveli receives approval in the European Union.Mon 09:29
• Novartis →

  Swiss-American multinational pharmaceutical corporation

  • Biotech and pharmaceutical companies in Greater Boston are seeing strategic investments, talent movement, and antibody development advances.Tue 13:27
  • Sean Maenpaa, with experience at Novartis and Celgene, was appointed SVP Business Development at Clovis Oncology.Fri 12:53

Related events

• Arise is seeking FDA approval for a drug as of October 7, 2026.Oct 7
• Hoffmann-La Roche sponsored a randomized trial involving Adagene's drug on October 17, 2026.Sat 20:36
• FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.Oct 15
• FDA approval expands patient access to therapies for ACCORD.Jul 10
• FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.Jun 22